Track antibody and ADC programs by leveraging CDD Vault’s chemically aware macromolecule capabilities. Heavy- and light- chain sequences can be registered and structurally annotated with domains, hin
...
How shall we generate antibody designs that balance affinity, specificity, developability, manufacturability, and safety while clearly quantifying model confidence? How shall we integrate formulation
...
The PioneerTM Antibody Discovery Platform is Bio-Rad’s biotherapeutic antibody generation service, centered around the Pioneer Antibody Library—one of the largest functional Fab libraries (225 billion
...
Navigating vast sequence space: How can teams efficiently explore enormous antibody repertoires to pinpoint candidates with the right balance of affinity, specificity, and developability? Balancing po
...
Strategies for improving antibody affinity during lead optimization. How does antibody affinity influence internalization, efficacy, and pharmacokinetics? To what extent do CDX and PDX models reflect
...
How have intracellular proteins historically been accessed by antibody therapeutics? How can intracellular proteins, when presented as pMHC, be targeted by TCR and TCR-mimicking antibody-based therape
...
How can molecular architecture be optimised to balance potency, stability and manufacturability? What strategies can reduce aggregation, chain mispairing and unwanted molecular interactions? How can
...
When you screen building blocks individually, what predicts (or fails to predict) how they'll behave once combined? How do you decide format before knowing your final pairing — or does format selectio
...
Bi- and multi-specific antibodies offer new ways to engage complex disease biology, but greater functionality also introduces important therapeutic design challenges. This session will share practical
...
Which developability assays are most informative for assessing candidates early on? -for stability, PK, high-concentration, immunogenicity, specificity, etc What are the most impactful in silico metho
...
Bispecific antibodies (BsAbs) offer transformative therapeutic potential, but their complex, non-native structure creates production challenges such as mispairing, low yield, and purification difficul
...
Why potent T-cell activation often comes at the cost of increased cytokine release. Strategies to improve the therapeutic window while maintaining robust antitumor efficacy. Challenges in translating
...
How can molecular architecture be optimised to balance potency, stability and manufacturability? What strategies can reduce aggregation, chain mispairing and unwanted molecular interactions? How can
...
A central challenge in drug development is determining whether a therapeutic achieves appropriate tissue distribution and produces biologically meaningful effects. We present a drug-inclusive spatial
...
Optimization of Drug Antibody Conjugates: Defining DAR, linker kinetics and stability, structural features and compositional stoichiometry, and analytical robustness Identification of limitations to d
...
How is the ADC space continuing to grow, and why does it remain heavily focused on similar payload types? Which different payloads may have greater potential for patients who do not respond to establi
...
How much of ADC linker selection is rational design versus platform default, and how rigorously are linker choices tested against alternatives? Are we over-indexing on linker chemistry rather than the
...
The current payload landscape – a TOPO1i world Development of novel single and dual payloads. What should we be looking for? Fit-for-purpose – identifying optimal payloads for specific tumor indicatio
...
How can we effectively identify the optimal payload–linker combinations to enhance the efficacy and safety of antibody-drug conjugates (ADCs)? What strategies can be employed to address and mitigate l
...
Are topoisomerase I inhibitor (TOP1i) payloads the default for solid tumor ADCs, or is the field over-converging on a single payload class with shared toxicity, resistance, and sequencing liabilities?
...
)
)
)
)
)
)
)
)
)
)
)
)